EFFECTIVENESS OF ICOSAPENT ETHYL IN MIDDLE EASTERN PATIENTS WITH DYSLIPIDEMIA

被引：0
|
作者：
Odeh, Mohamed [1 ]
Afandi, Bachar [2 ]
机构：
[1] Sulaiman Al Habib Med Grp, Riyadh, Saudi Arabia
[2] Tawam Hosp, Abu Dhabi, U Arab Emirates
来源：
ATHEROSCLEROSIS | 2024年 / 399卷
关键词：
D O I：
10.1016/j.atherosclerosis.2024.118701
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Icosapent Ethyl: Niche Drug or for the Masses?
    Najdat Bazarbashi
    Michael Miller
    Current Cardiology Reports, 2020, 22
  • [22] Icosapent ethyl: scientific and legal controversies
    Curfman, Gregory
    Shehada, Emile
    OPEN HEART, 2021, 8 (01):
  • [23] Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada
    Lachaine, Jean
    Charron, Jean -Nicolas
    Gregoire, Jean C.
    Hegele, Robert A.
    Leiter, Lawrence A.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 295 - 308
  • [24] COST-EFFECTIVENESS ANALYSIS OF ICOSAPENT ETHYL (IPE) FOR THE REDUCTION OF THE SEVERE HYPERTRIGLYCERIDEMIA (HTG) IN CHINA
    Shen, Y.
    Chen, P.
    He, X.
    VALUE IN HEALTH, 2024, 27 (06) : S250 - S251
  • [25] Consistent Cost-effectiveness of Icosapent Ethyl Across Patient Profiles From REDUCE-IT
    Zhang, Zugui
    Bhatt, Deepak L.
    Dolman, Sarahfaye
    Boden, William E.
    Steg, Philippe G.
    Miller, Michael
    Brinton, Eliot A.
    King, Jordan B.
    Bress, Adam P.
    Jacobson, Terry A.
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    Kolm, Paul
    Weintraub, William S.
    CIRCULATION, 2020, 142
  • [26] Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
    Gaba, Prakriti
    Bhatt, Deepak L.
    Steg, Gabriel
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Ketchum, Steven B.
    Juliano, Rebecca A.
    Jiao, Lixia
    Doyle, Ralph T.
    Granowitz, Craig
    Tardif, Jean-Claude
    Giugliano, Robert P.
    Martens, Fabrice M. A. C.
    Gibson, C. Michael
    Ballantyne, Christie M.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (17) : 1660 - 1671
  • [27] Icosapent ethyl: insights into cardiovascular residual risk
    Scala, Antonella
    Casella, Michela
    Bernelli, Chiara
    Biscaglia, Simone
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2023, 71 (04) : 359 - 362
  • [28] Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2020, 62 (1591): : 17 - 18
  • [29] Effectiveness of Icosapent Ethyl on First and Total Cardiovascular Events in the Metabolic Syndrome: REDUCE-IT MetSyn
    Miller, Michael
    Bhatt, Deepak
    Brinton, Eliot A.
    Jacobson, Terry A.
    Steg, Philippe G.
    Pineda, Armando L.
    Ketchum, Steven
    Doyle, Ralph
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    CIRCULATION, 2023, 148
  • [30] Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
    Bhatt, Deepak L.
    Steg, P. Gabriel
    Miller, Michael
    Brinton, Eliot A.
    Jacobson, Terry A.
    Ketchum, Steven B.
    Doyle, Ralph T., Jr.
    Juliano, Rebecca A.
    Jiao, Lixia
    Granowitz, Craig
    Tardif, Jean-Claude
    Ballantyne, Christie M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01): : 11 - 22
12345